NCT07450859 2026-04-22
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
BicycleTx Limited
Phase 2 Recruiting
Clinical Trials
91 trialsNCT05564377 2026-04-21
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03841617 2026-04-20
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04927416 2026-04-20
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06792695 2026-04-20
CANTOR
AstraZeneca
Phase 2 Recruiting
NCT07283731 2026-04-17
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07285993 2026-04-17
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT07336238 2026-04-17
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
University of Washington
Phase 2 Recruiting
NCT04879121 2026-04-16
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03682289 2026-04-15
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Recruiting
NCT05327010 2026-04-14
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05821556 2026-04-14
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
National Cancer Institute, Naples
Phase 2 Recruiting
NCT03907475 2026-04-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04550494 2026-04-13
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05222620 2026-04-13
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Mayo Clinic
Phase 2 Recruiting
NCT06067503 2026-04-13
Biomarkers to Detect Endocrine Therapy Resistance
University of Wisconsin, Madison
Phase 2 Recruiting
NCT06311214 2026-04-13
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT07423078 2026-04-13
WOLF
University of Pittsburgh
Phase 2 Recruiting
NCT06790602 2026-04-09
SWITCH
University of California, San Diego
Phase 2 Recruiting
NCT07042685 2026-04-09
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT06634875 2026-03-31
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Buzzard Pharmaceuticals
Phase 2 Recruiting
NCT07312292 2026-03-30
RADIANT
UMC Utrecht
Phase 2 Recruiting
NCT07483983 2026-03-27
UNLOCK ASP3082
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT02133196 2026-03-24
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06769698 2026-03-23
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT07477457 2026-03-17
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05755113 2026-03-12
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
QBiotics Group Limited
Phase 2 Recruiting
NCT05607108 2026-03-11
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07057596 2026-03-06
NEO-TB
Grupo Español Multidisciplinar de Melanoma
Phase 2 Recruiting
NCT04771520 2026-03-02
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05686226 2026-02-27
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT07282834 2026-02-27
Charlie-2
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 2 Recruiting
NCT07432295 2026-02-25
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
Phase 2 Recruiting
NCT06630416 2026-02-24
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT06058988 2026-02-23
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07193394 2026-02-23
H3RAKLES
Institut Curie
Phase 2 Recruiting
NCT07407465 2026-02-17
CHIMERA
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT06358677 2026-02-13
FACE
University of Utah
Phase 2 Recruiting
NCT05726383 2026-02-10
Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma
Hackensack Meridian Health
Phase 2 Recruiting
NCT06778408 2026-02-05
HART
University of Vermont Medical Center
Phase 2 Recruiting
NCT07176312 2026-02-04
ZANGEA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT07183319 2026-02-02
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
Phase 2 Recruiting
NCT05010031 2026-01-23
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05419518 2026-01-23
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT05502315 2026-01-23
CANOPY
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05673928 2026-01-21
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT05716516 2026-01-14
ESTHER
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT07079462 2025-12-24
Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis
Fudan University
Phase 2 Recruiting